Contribution of Metabolic Tumor Volume and Total Lesion Glycolysis to Predict Prognosis in Early-Stage Lung Cancer at Preoperative Staging

Karaman, Elanur; Goksel, Sibel; Tülüce, Kerim

doi:10.29271/jcpsp.2022.06.740

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [ 195 ] Maackia amurensis NSCLC Cell lines • Intrinsic/mitochondrial pathway • Adjuvant chemotherapeutic [ 196 ] LCa • Metabolic characteristics and disordered • Subtyping of lung tumors [ 197 ] Glutamate Lung cancer Clinical trial • Plasma glutamate • Amino acids • β-Hydroxybutyrate • Energy-balance-related metabolites [ 70 ] GLUT1, PCK1 and PCK2 NSCLC Cell lines and Human tissues • Hypoxia regulated ○ Glycolysis ○ Gluconeogenesis • Future therapeutic strategies [ 198 ] Kinase NSCLC Human tissues • Focal adhesion kinase • C-terminal Src kinase • Potential molecular biomarkers [ 199 ] ALDOA NSCLC Cell lines • Reduced ○ Extracellular lactate ○ Nuclear distribution of PKM2 intracellular ATP levels • Elevated extracellular glucose • EGFR/MAPK pathway is partly modulated [ 200 ] TMPRSS11B Human bronchial epithelial cells (HBECs) Cell lines • Enhances ○ Lactate export ○ Glycolytic metabolism • Transformation of immortalized cells [ 201 ] GLUT1 NSCLC Retrospective study • Micropapillary/solid histology lymphovascular invasion • Advanced pTNM stage • Heterogeneity in patients [ 202 ] Physcion 8-O-β-glucopyranoside (PG) Lung cancers Cell lines and mice model • Mitochondria-dependent apoptosis ○ miR-21/PTEN/Akt/GSK3β signaling pathway. • Lung tumor energy utilization [ 203 ] …”

Section: Blocking Common Nsclc Metabolic Pathways As Anti-nsclcmentioning

confidence: 99%

Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine

Bajinka,

Ouedraogo,

Golubnitschaja

et al. 2024

EPMA Journal

View full text Add to dashboard Cite

Energy metabolism is a hub of governing all processes at cellular and organismal levels such as, on one hand, reparable vs. irreparable cell damage, cell fate (proliferation, survival, apoptosis, malignant transformation etc.), and, on the other hand, carcinogenesis, tumor development, progression and metastazing versus anti-cancer protection and cure. The orchestrator is the mitochondria who produce, store and invest energy, conduct intracellular and systemically relevant signals decisive for internal and environmental stress adaptation, and coordinate corresponding processes at cellular and organismal levels. Consequently, the quality of mitochondrial health and homeostasis is a reliable target for health risk assessment at the stage of reversible damage to the health followed by cost-effective personalized protection against health-to-disease transition as well as for targeted protection against the disease progression (secondary care of cancer patients against growing primary tumors and metastatic disease).The energy reprogramming of non-small cell lung cancer (NSCLC) attracts particular attention as clinically relevant and instrumental for the paradigm change from reactive medical services to predictive, preventive and personalized medicine (3PM). This article provides a detailed overview towards mechanisms and biological pathways involving metabolic reprogramming (MR) with respect to inhibiting the synthesis of biomolecules and blocking common NSCLC metabolic pathways as anti-NSCLC therapeutic strategies. For instance, mitophagy recycles macromolecules to yield mitochondrial substrates for energy homeostasis and nucleotide synthesis. Histone modification and DNA methylation can predict the onset of diseases, and plasma C7 analysis is an efficient medical service potentially resulting in an optimized healthcare economy in corresponding areas. The MEMP scoring provides the guidance for immunotherapy, prognostic assessment, and anti-cancer drug development. Metabolite sensing mechanisms of nutrients and their derivatives are potential MR-related therapy in NSCLC. Moreover, miR-495-3p reprogramming of sphingolipid rheostat by targeting Sphk1, 22/FOXM1 axis regulation, and A2 receptor antagonist are highly promising therapy strategies. TFEB as a biomarker in predicting immune checkpoint blockade and redox-related lncRNA prognostic signature (redox-LPS) are considered reliable predictive approaches.Finally, exemplified in this article metabolic phenotyping is instrumental for innovative population screening, health risk assessment, predictive multi-level diagnostics, targeted prevention, and treatment algorithms tailored to personalized patient profiles—all are essential pillars in the paradigm change from reactive medical services to 3PM approach in overall management of lung cancers. This article highlights the 3PM relevant innovation focused on energy metabolism as the hub to advance NSCLC management benefiting vulnerable subpopulations, affected patients, and healthcare at large.

show abstract